The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway

There is a growing body of evidence supporting the use of epigenetic therapies in the treatment of multiple myeloma. We show the novel HDAC inhibitor CHR-3996 induces apoptosis in myeloma cells at concentrations in the nanomolar range and with apoptosis mediated by p53 and caspase pathways. In addit...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Emma M., Zhang, Lei, Walker, Brian A., Davenport, Emma L., Aronson, Lauren I., Krige, David, Hooftman, Leon, Drummond, Alan H., Morgan, Gareth J., Davies, Faith E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627310/
https://www.ncbi.nlm.nih.gov/pubmed/26015393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627310/
https://www.ncbi.nlm.nih.gov/pubmed/26015393

Ejemplares similares